For most of the last decade, UnitedHealth Group looked like a machine that printed money the bigger it got. Revenue climbed every year, margins held steady around 6%, and the stock rewarded patience. Then, starting in late 2023, something broke the pattern: the bills coming in from hospitals and pharmacies began rising faster than the premiums going out. The company kept growing, but the profit attached to each dollar of that growth quietly collapsed. Understanding why, and whether the worst is behind it, is the whole story right now.
In one breath
UnitedHealth’s revenue has grown nearly 75% since 2020, but its net margin has fallen from 6% to under 3%, meaning the business is earning less on every dollar than it did when it was much smaller. The stock, at roughly $424, is priced at a multiple far above its own decade median, implying the market expects a strong recovery in profitability. The open question is whether the medical cost pressures driving that margin collapse, especially in commercial insurance, are truly turning, or whether the recovery the price assumes is still years away.
Two numbers that should not coexist
Here is the contrast that opens this story: revenue in fiscal year 2025 reached $447.6 billion, the largest single-year top line in the company’s history, yet earnings per share fell to $13.23, down from $23.86 just two years earlier. A business can grow its sales by nearly $80 billion in two years and still earn less per share. That is not a paradox you see often, and it is the tension this article is built around.
The math behind it is simple. An insurer collects premiums and pays medical claims. The medical loss ratio, or MLR, is the share of each premium dollar that goes straight back out as claims payments. Think of it like a restaurant: if the MLR is 87 cents, only 13 cents is left to cover the kitchen, the staff, and any profit. When the MLR rises, the margin shrinks, even if the restaurant is serving more tables than ever.
The 2025 annual filing shows the full-year MLR hit 88.9%, up from 85.5% in 2024. The fourth quarter of 2025 was worse still, reaching 92%, the highest quarterly reading in eight years. That single quarter was essentially a break-even proposition on the insurance side of the business. The consequence is direct: net margin fell from 6.2% in 2022 to 2.7% in 2025, meaning the business now keeps less than three cents of profit from every dollar it takes in.
How the bills got so big
The acceleration did not arrive all at once. The first warning came in late 2023, when Healthcare Dive reported that seniors were flooding back into hospitals for orthopedic and cardiac procedures they had deferred during the pandemic. That backlog of care, combined with a new wave of seasonal illness, pushed the MLR to its highest point since the early COVID period.
Then came the pharmacy bill. GLP-1 drugs, the weight-loss and diabetes medications that have become household names, went from a niche line item to a structural cost. According to UnitedHealth’s own annual health trends report, GLP-1s accounted for more than 10% of annual pharmacy claims in 2026, up from under 7% in 2023. That shift happened in roughly three years. Pharmacy costs overall rose 11% in 2025, according to the same source, and national prescription drug spending is projected by Health Affairs to grow 10% to 12% in 2026 compared to 2025.
The commercial insurance side carries a separate wound. The No Surprises Act, a federal law designed to protect patients from unexpected out-of-network bills, created an independent dispute resolution process that providers have used aggressively to win higher payments from insurers. According to the Q2 2026 results release, commercial medical cost trends are running modestly above 11%, and the company said commercial margin recovery is now expected to be delayed beyond 2027. That is a long runway for a problem that is already two years old.
The Q2 turn, and what it does and does not prove
The most recent data point is genuinely better. The Q2 2026 results, reported July 16, show a consolidated MLR of 86.7%, down from 89.4% in the same quarter a year earlier. That is nearly three percentage points of improvement in twelve months, driven by benefit redesign, repricing, and exiting some Medicare markets where costs had outrun premiums. The company raised its full-year adjusted earnings guidance to $19.50 to $20.00 per share, a meaningful step up from where the stock was priced for much of the past year.
The comparison with the nearest competitor adds context. Elevance Health, formerly Anthem, reported a benefit expense ratio of 89.7% for Q2 2026, about three points worse than UnitedHealth’s reading. Both companies are fighting the same cost environment, but UnitedHealth’s Medicare repricing appears to be working faster. That said, Humana and CVS Health’s Aetna unit had not yet reported Q2 figures as of this writing, so the full industry picture is incomplete.
The honest limit here is that one improved quarter does not resolve the commercial problem. The company itself said so. A business where the largest segment, commercial insurance, faces cost trends above 11% with no clear moderation in sight is still a business under pressure, even if the Medicare side is stabilizing.
What the price is paying for
This is where the math and the mood, the two lenses we use to read any stock, pull in different directions. The math is what the filed numbers show: margins at multi-year lows, EPS roughly half what it was in 2023, and a commercial cost problem the company itself says extends past 2027. The mood is what the market is currently paying for that math: a price-to-earnings multiple of 32.9 times, against a decade median of 23.5 times, which puts the stock at the 99th percentile of its own valuation history, according to our data.
A multiple above the decade median makes sense when earnings are depressed and a recovery is expected. The market is, in effect, paying today for profits it expects to arrive later. Morgan Stanley raised its valuation estimate to $529 on July 17, and JPMorgan raised its to $516 on July 21, according to TIKR’s analysis of the Q2 reaction. The sell-side consensus, as reported there, skews toward the bullish end of the rating spectrum, context readers can weigh against the commercial cost uncertainty the company itself has flagged. The mood is optimistic.
The tension is that the price-to-sales ratio tells the opposite story: at 0.9 times sales, the stock sits at the 22nd percentile of its own decade history, meaning the market is paying less per dollar of revenue than it usually does. A business priced at a premium on earnings but a discount on revenue is one where the market is betting heavily on margin recovery. If that recovery arrives on schedule, the earnings multiple looks reasonable. If the commercial cost problem lingers past 2027 as management warned, the earnings multiple looks like a bet that did not pay.
Reading the numbers
- Medical loss ratio (MLR), Q2 2026: 86.7%. This is the share of premium revenue paid out as medical claims. Think of a household insurance policy that costs $1,000 a month: an 86.7% MLR means $867 goes straight to paying claims, leaving $133 for everything else. The Q2 2026 figure, from the Q2 results release, is down from 89.4% a year earlier, a real improvement, but still well above the levels that produced 6% net margins earlier in the decade.
- Full-year MLR, 2025: 88.9%. Filed in the 2025 10-K, up from 85.5% in 2024. Each percentage point of MLR increase on a $447 billion revenue base represents roughly $4.5 billion less available for operating costs and profit. The three-and-a-half-point rise from 2024 to 2025 erased more than the company earns in a typical year.
- Commercial medical cost trend, Q2 2026: modestly above 11%. This is the year-over-year rate at which medical claims costs are rising in the commercial insurance segment, per the Q2 2026 press release. A household paying $600 a month in premiums last year would, at an 11% trend, be costing the insurer the equivalent of $666 in claims this year. When premiums were priced assuming a lower trend, the insurer absorbs the gap.
- P/E ratio: 32.9 times, versus a decade median of 23.5 times. A price-to-earnings multiple is the price tag per dollar of annual profit, the way a house price-to-rent ratio tells you how many years of rent you are paying upfront. At 32.9 times, the market is paying nearly 40% more per dollar of profit than it has on average over the past decade, according to our data. That premium is a bet on earnings recovery.
- EPS, FY2025: $13.23, versus FY2023: $23.86. Earnings per share is the profit attributed to each share of stock. The drop from $23.86 to $13.23 in two years, filed in the 2025 10-K, means each share is now generating roughly 45% less profit than it did in 2023. The raised 2026 guidance of $19.50 to $20.00, if achieved, would represent a partial but not complete recovery to prior levels.
For the standing yardsticks on UnitedHealth Group: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: UnitedHealth Group.
Sources
- UnitedHealth Group Q2 2026 Results Release
- UnitedHealth Group Q2 2026 Press Release (Newsroom)
- UNH 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
- UNH 10-Q, quarter ended March 31, 2026 (SEC EDGAR)
- Healthcare Dive: UnitedHealth medical spending surge
- UnitedHealth Annual Health Trends Report
- Health Affairs: National health spending projections 2026
- Elevance Health Q2 2026 Earnings Release
- TIKR: UNH Q2 2026 analyst reaction
